NRX Pharmaceuticals (NRXP) Depreciation & Amortization (CF) (2020 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Depreciation & Amortization (CF) of $63000.0 for Q1 2026, up 6200.0% year-over-year from $1000.0 in Q1 2025, and up 50.0% quarter-over-quarter from $42000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $63000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 6200.0% year-over-year to $63000.0; the TTM figure through Mar 2026 stood at $111000.0 (up 2120.0% YoY), while the FY2025 annual figure was $70000.0, up 1300.0% from the prior year.
- Depreciation & Amortization (CF) climbed to $63000.0 in Q1 2026 per NRXP's latest filing, from $42000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $63000.0 in Q1 2026 and bottomed at -$20000.0 in Q2 2025.
- Historically, Depreciation & Amortization (CF) has averaged $7411.8 across 5 years, with a median of $1000.0 in 2022.
- Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) sank 2100.0% — and 2026, when it jumped 6200.0%.
- NRX Pharmaceuticals' Depreciation & Amortization (CF) stood at $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then soared by 4100.0% to $42000.0 in 2025, then jumped by 50.0% to $63000.0 in 2026.
- Business Quant data shows NRXP's Depreciation & Amortization (CF) at $63000.0 in Q1 2026, $42000.0 in Q4 2025, and $26000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 71,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63,000.00 |
| Mar 31, 2026 | 63,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Jun 30, 2025 | -20,000.00 |
| Jun 30, 2025 | -20,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |